This study is currently not recruiting participants.

SIMPONI? to Arrest ?-cell Loss in Type 1 Diabetes

Study on Investigational Medication for Type 1 Diabetes in Children and Young Adults

Not Recruiting
6 years - 21 years
All
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to see if golimumab can preserve beta-cell function in children and young adults with newly diagnosed Type 1 Diabetes (T1D).

Detailed description of study

The purpose of this study is to see if golimumab can preserve beta-cell function in children and young adults with newly diagnosed Type 1 Diabetes.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: type 1 diabetes
  • Age: 6 years - 21 years
  • Gender: All

This study investigates the effect of an investigational medication on preserving beta-cell function in children and young adults who have been newly diagnosed with Type 1 Diabetes. Type 1 Diabetes is a condition where the body's immune system attacks insulin-producing cells in the pancreas, known as beta cells.

Participants in the study will receive either the investigational medication or a placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine. The study will monitor the impact of the investigational medication on the participants' beta-cell function.

  • Who can participate: Children and young adults aged X to Y who have been newly diagnosed with Type 1 Diabetes are eligible to participate.
  • Study details: Participants will receive either the investigational medication or a placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine.
Updated on 19 Feb 2024. Study ID: 1607570134

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team